Results 151 to 160 of about 41,454 (219)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. [PDF]

J Infect Dis, 2019
Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, Kapiga S, Grosskurth H, Kalluvya S, Bockstal V, Anumendem D, Luhn K, Robinson C, Douoguih M, Watson-Jones D.   +14 more
europepmc   +1 more source

Global Health Preparedness Frameworks and Recombinant Vaccine Platforms: A Public Health Perspective on Regulations and System Readiness. [PDF]

Vaccines (Basel)
Russo L, Villani L, Ieraci R, Ricciardi W.   +3 more
europepmc   +1 more source

Gorilla journal : nr. 32 / journal of Berggorilla- & Regenwald-Direkthilfe [PDF]

, 2006
Berggorilla- & Regenwald-Direkthilfe e.V.
core   +1 more source

Virus Biomimetic-Delivery Systems for the Production of Vaccines. [PDF]

Biomimetics (Basel)
Barbinta-Patrascu ME, Negut I, Bita B.
europepmc   +1 more source

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. [PDF]

J Infect Dis, 2019
Mutua G, Anzala O, Luhn K, Robinson C, Bockstal V, Anumendem D, Douoguih M.   +6 more
europepmc   +1 more source

Healthcare Worker Attitudes and Perceptions toward Ebola Vaccine, United States, 2024. [PDF]

Emerg Infect Dis
Goswami R, Lo Piccolo A, Miller R, Frank M, Levine C, Chan J.   +5 more
europepmc   +1 more source

Long non-coding RNAs in response to Ebola virus vaccine-induced immunity. [PDF]

Front Immunol
Mamede I, Luschër-Dias T, Moscardini IF, Gonzales-Dias P, Marinho B, Marcon F, Dominguez Crespo Hirata T, Eichberg M, Medaglini D, Harandi AM, Siegrist CA, Ottenhoff THM, Santoro F, Gonçalves A, Ferreira DM, Polidoro R, Franco GR, Amaral PP, Nakaya H, Addo MM, VSV-EBOPLUS Consortium .   +20 more
europepmc   +1 more source

Safety and immunogenicity of rVSVΔG-ZEBOV-GP vaccination when dosed concurrent with mRNA COVID-19 vaccine booster doses in healthy African adults (EbolaCov): protocol for a phase IV, single-centre, single-blinded, randomised controlled trial. [PDF]

BMJ Open
Gokani K, Taylor A, Packham A, Musabyimana JP, Shema H, Mutabaruka A, Roche S, Takwoingi Y, Umuhoza C, Nyombayire J, Muvunyi C, Green C.   +11 more
europepmc   +1 more source

Rarely listed essential medicines in 158 national lists. [PDF]

J Pharm Policy Pract
Ul Haq MZ, Heredia C, Rizvi A, Workentin A, Persaud N.   +4 more
europepmc   +1 more source

The systematic use of cost-effectiveness criteria to inform decisions about the removal of items from publicly-financed 'benefits packages'. A report commissioned by the Department of Health and prepared by the London School of Hygiene and Tropical Medicine [PDF]

, 2007
Ettelt, S, Mays, N, Nolte, E, Thomson, S
core   +2 more sources